Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Prince Harry, Elton John Ordered to Pay £9.54 Million in Daily Mail Legal Costs 
Sara Duterte Posts Bail Over Grave Threats Case 
Brazil Court Suspends Sigma Lithium Mine Operations 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Judge Rejects Minnesota Bid to Force ICE Agent Extradition 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
New Mexico Sues DOJ Over Unredacted Jeffrey Epstein Files Amid Ongoing Investigation 
Huawei Launches Mate XT2 Foldable Phone in China 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
3 clinical-grade skincare creams you really shouldn’t buy online 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Add as a preferred source on Google
A U.S. federal jury has ordered Japan-based Takeda Pharmaceutical to pay approximately $885 million in damages after finding the company liable for delaying the release of a generic version of its constipation drug Amitiza through an alleged anticompetitive agreement. The verdict was delivered Monday in a Boston federal court and marks a major development in ongoing “pay-for-delay” pharmaceutical litigation in the United States.
The lawsuit was brought by pharmacies, insurers, retailers, and health funds, including CVS Health and Walgreens, which argued that Takeda’s actions forced buyers to continue paying inflated prices for Amitiza for years. Under U.S. antitrust laws, the damages awarded could eventually be tripled, potentially exposing Takeda to several billion dollars in financial liability.
The legal dispute focused on a 2014 settlement between Takeda, Sucampo Pharmaceuticals, and generic drugmaker Par Pharmaceutical. Par had sought approval from the U.S. Food and Drug Administration to launch a generic version of Amitiza after challenging the validity of the drug’s patents. However, the companies reached an agreement allowing Par to delay the launch until January 2021 while receiving access to distribute an authorized generic version of the drug under a profit-sharing arrangement.
Plaintiffs argued the deal effectively acted as a $210 million payoff that postponed lower-cost competition for nearly six years. Takeda denied wrongdoing and maintained during the trial that the agreement was lawful and encouraged competition. The company also stated it plans to aggressively appeal the ruling.
The jury awarded $474.9 million to direct purchasers and $63.2 million to insurers and other end payors. CVS received $191 million in damages, while Walgreens was awarded $121 million.
Despite the ruling, Takeda said it does not expect a material impact on its FY2026 financial guidance aside from possible effects on adjusted free cash flow. Takeda shares rose 0.6% Tuesday morning, outperforming Japan’s Nikkei 225 index, which declined 0.3%.
